Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1

Interventions

Rituximab 33Cyclophosphamide 23Filgrastim 18Peripheral Blood Stem Cell Transplantation 16Etoposide 13fludarabine phosphate 12Vincristine 12Prednisone 11Bortezomib 11sargramostim 10Radiotherapy 10Doxorubicin 8Cytarabine 8Cyclosporine 8Vorinostat 7Lenalidomide 7Cisplatin 7Biopsy 7tanespimycin 6Melphalan 6Magnetic Resonance Spectroscopy 6Ifosfamide 6bryostatin 1 5alvocidib 5aldesleukin 5Specimen Handling 5Methylprednisolone 5Methotrexate 5Interferon-alpha 5Gemcitabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, Follicular × Methylprednisolone Acetate × Clear all
NCT04599634 2025-02-04

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
11 enrolled 16 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡